INmune Bio stockholders approve Third Amended 2021 Stock Incentive Plan, increasing share reserve to ~9.16M shares

Inmune Bio, Inc.

Stockholders approved Third Amended 2021 Stock Incentive Plan, increasing share reserve from 6.5M to 9,158,525 shares.
Plan includes evergreen provision: annual auto-increase on first trading day of 2027-2031, up to 10% of outstanding shares.
All five director nominees elected: David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, Marcia Allen.
Ratification of CBIZ CPAs P.C. as independent auditor for FY2026 approved with 17,293,255 votes for.
Broker non-votes: 8,501,317 shares on director elections and plan vote.

item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Inmune Bio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Proposal One: Election of Directors. Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company’s stockholders and until his or her successor is elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes David Moss 6,834,995 2,120,682 8,501,317 J. Kelly Ganjei 5,955,609 3,000,068 8,501,317 Tim Schroeder 6,622,916 2,332,761 8,501,317 Scott Juda, JD 7,508,310 1,447,367 8,501,317 Marcia Allen 6,342,910 2,612,767 8,501,317 1

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Inmune Bio, Inc. shareholders approved Ratification of Appointment of Independent Auditor at the 2026-06-16 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Proposal Two: Ratification of Appointment of Independent Auditor. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2026. For Against Abstentions Broker Non-Votes 17,293,255 107,064 56,675 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Inmune Bio, Inc. shareholders approved Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan at the 2026-06-16 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Proposal Three: Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. As noted above, the stockholders approved the Amended Plan. For Against Abstentions Broker Non-Votes 6,085,086 2,775,224 95,367 8,501,317

View on SEC.gov

Browse all shareholder votes →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-069611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.